IMNN · Imunon, Inc. · Executive Compensation
$1.49
+0.04 (+2.41%)
At close · Sep 11
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$8.14M
Shares
5.61M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Stacy Lindborg | President & CEO | $1,029,349 |
| Michael Tardugno | Executive Chairman & former interim CEO | $605,899 |
| Douglas Faller | Chief Medical Officer | $589,810 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Stacy Lindborg | President & CEO | $1,189,339 |
| Jeffrey Church | Former Executive VP & CFO | $807,987 |
| Khursheed Anwer | Executive VP & CSO | $741,680 |
| Michael Tardugno | Executive Chairman & former interim CEO | $734,810 |
| David Gaiero | CFO | $280,000 |
| Corinne Le Goff | Former President and CEO | $148,869 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Corinne Le Goff | Former President and CEO | $1,055,814 |
| Khursheed Anwer | Executive VP & CSO | $680,159 |
| Jeffrey Church | Former Executive VP & CFO | $679,922 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Tardugno | Executive Chairman | $2,085,391 |
| Corinne Le Goff | President & CEO | $883,794 |
| Nicholas Borys | Executive VP & CMO | $707,122 |
| Khursheed Anwer | Executive VP & CSO | $678,658 |
| Jeffrey Church | Executive VP & CFO | $636,631 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Michael Tardugno | Executive Chairman | $2,312,625 |
| Jeffrey Church | Executive VP & CFO | $1,087,963 |
| Khursheed Anwer | Executive VP & CSO | $1,020,478 |
| Nicholas Borys | Executive VP & CMO | $789,947 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Michael Tardugno | Chairman, President & CEO | $1,429,073 |
| Nicholas Borys | Executive VP & CMO | $756,042 |
| Jeffrey Church | Executive VP & CFO | $696,423 |
| Khursheed Anwer | Executive VP & CSO | $643,848 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Michael Tardugno | Chairman, President & CEO | $1,251,640 |
| Nicholas Borys | Executive VP & CMO | $700,708 |
| Khursheed Anwer | Executive VP & CSO | $650,698 |
| Jeffrey Church | Executive VP & CFO | $647,167 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Michael Tardugno | Chairman, President & CEO | $2,950,091 |
| Nicholas Borys | Executive Vice President & CMO | $1,155,246 |
| Jeffrey Church | Executive Vice President & CFO | $1,126,392 |
| Khursheed Anwer | Executive Vice President & CSO | $666,642 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Josh Blacher | interim Chief Financial Officer | Appointed | 2026-06-30 |
| Jeffrey Church | interim Chief Financial Officer | Retired | 2026-06-30 |
| Christine A. Pellizzari | Class I director | Appointed | 2026-06-16 |
| Frederick J. Fritz | Class I director | Appointed | 2026-06-16 |
| Khursheed Anwer | Executive Vice President and Chief Scientific Officer | Retired | 2026-02-05 |
| Jeffrey Church | interim Chief Financial Officer | Appointed | 2026-01-07 |
| Kimberly Graper | interim Chief Financial Officer | Resigned | 2026-01-07 |
| Kimberly Graper | interim Chief Financial Officer | Appointed | 2025-06-13 |
| David Gaiero | interim Chief Financial Officer | Terminated | 2025-06-13 |
| Douglas Faller | Chief Medical Officer | Appointed | 2025-02-10 |
| Susan Eylward | General Counsel and Corporate Secretary | Appointed | 2024-10-07 |
Key facts
CIK
749647
CUSIP
15117N701
13F (30d)
17 filings
17 filers
Visit website
Investor relations